Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.Journal of cardiovascular electrophysiology · 2019
   Trial
2. Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing.Seminars in thrombosis and hemostasis · 2026
   Review
3. Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay.Research and practice in thrombosis and haemostasis · 2026
   Article
4. Oral Anticoagulation Therapy: An Update on Usage and Costs in the Endemic COVID-19 Era.Journal of clinical medicine · 2025
   Article
5. Post-analytical Issues in Hemostasis and Thrombosis Testing: An Update.Methods in molecular biology (Clifton, N.J.) · 2023
   Article
6. Laboratory Testing for Activated Protein C Resistance (APCR): An Update.Methods in molecular biology (Clifton, N.J.) · 2023
   Article
7. Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients.Diagnostics (Basel, Switzerland) · 2021
   Article
8. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2021
   Article
9. Management of an acute cerebral embolic infarct with thrombolysis and mechanical thrombectomy in the presence of an aortic arch floating thrombus.BMJ case reports · 2021
   Article
10. Hypercoagulable workup in a community hospital setting: to test or not to test; that is the question.Journal of community hospital internal medicine perspectives · 2019
    Article
11. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article

Corrections and comments

• Comment on
  Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as